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Background: This study aimed to assess construction and expression of CagA recombi-
nant protein of Helicobacter pylori (H. pylori) in Escherichia coli (E. coli) BL21.  
 
Methods: Bioinformatics was used in designing the desired gene by Gene Runner. 
Next, the construct was subcloned to pET21b vector and this process was confirmed by 
Polymerase Chain Reaction (PCR), enzyme digestion and sequencing techniques. 
Then, it was cloned in the Escherichia coli BL21 as an expression host. Expression of pro-
tein was verified using sodium dodecyl sulfate- polyacrylamide gel electrophoresis 
(SDS-PAGE) and Western blotting technique. For purification of the protein, the Ni-
NTA column was used. Protein concentration was determined by the Bicinchoninic 
Acid Protein Assay Kit (Parstoos). Finally, Western blotting was performed using CagA 
antibodies and normal human serum for determining immunogenicity feature with 
human antiserum. 
 
Results: According to the results of the present study, CagA construct was cloned into 
the pET21b vector and after confirmation and cloning in host expression, recombinant 
protein with the size of 38 kDa was successfully expressed and purified. The recombi-
nant CagA protein showed immunogenicity characteristics with human antiserum. 
 
Conclusion: In conclusion, only 5′-end of recombinant protein CagA with high immu-
nogenicity effects was successfully constructed, cloned and expressed.  Also, CagA re-
combinant protein showed good immunogenicity activity with human antiserum.  
 
 






Overall, almost 75% of the whole gastric cancers 
and 63.4% of the total stomach ulcers are caused by 
Helicobacter pylori (H. pylori) 1,2. The most important 
concern about H. pylori is the emergence of drug-
resistant strains which necessitate the use of a proper 
vaccine against pathogenic strains 3,4. So far, several 
virulence factors have been identified for H. pylori 5,6. 
One of them is CagA that is encoded by cagA gene. 
CagA protein is one of the most immunogenic proteins 
of H. pylori and is also associated with type 1 strains 






Most studies used carbonic end of cagA, due to the 
changes and diversity in its C-terminal fragment in 
various isolates of H. pylori, but the 5′- end of cagA 
has no usable restriction endonuclease sites as well as 
EPIYA motif (this region is toxic for host cells) 9 and 
contains sequences with properties of conserved re-
gions with the high induction power of the immune 
system (both cellular and humoral arms of immune 
system, especially cellular arm which is most important 
in vaccine design) 10,11. Also, the whole protein of 
CagA is very difficult to express and purify, and due to 
the antigenic changes, diversity, and disturbance in the 
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folding of the antigen epitopes, the complete fragment 
of CagA would not be able to stimulate an appropriate 
immune response 12. On the other hand, the epitopes of 
its protected regions may not be accessible to the im-
mune system as a result of inappropriate folding 13,14. 
Therefore, in this study, this antigenic fragment was 
selected to be investigated.  
According to the importance of CagA protein in 
diseases related to H. pylori, this study aimed to assess 
construction and expression of CagA recombinant pro-
tein of H. pylori in Escherichia coli (E. coli) as an 
expression host.  
 
Materials and Methods 
 
Construction of recombinant plasmid 
At first, as mentioned in previous work 1, the se-
quence of cagA gene of H. pylori strain 26695 was 
obtained through searching data banks (NCBI, UniProt, 
…). Sequence 841 bp of 5′-end of cagA was chosen 
and two enzymes cutting sites of BamHI and SalI 
(Fermentas, Lituania) were put in 5′ and 3′ ends of 
cagA fragment. Primer 3 and gene runner tools were 
used for designing primers.  Bioinformatics studies 
were performed using associated software in silico. 
Then, the desired fragment was sent to Generay Com-
pany (China) for synthesis. DNA construct was cloned 
into the Multiple Cloning Sites (MCS) of the PGH vec-
tor. After that, the E. coli strain Top10 transformed. E. 
coli transformation was done on an LB agar plate con-
taining 100 mg/ml of ampicillin. PCR, enzyme diges-
tion and sequencing were used for confirmation of 
transformed colonies. PGH-G plasmids were extracted 
from E. coli (Top10) using extraction plasmid kit 
(Genet Bio Inc., South Korea) and double digestion 
was performed using RE enzymes to get cagA frag-
ment based on manufacturer’s directions. To create a 
recombinant expression vector, double digested cagA 
fragment was cloned into pET21b. The ligating reac-
tion was used to enter the cagA gene into the expres-
sion vector of pET21b. The ligation reaction was per-
formed in the presence of T4 DNA ligase enzyme and 
ligase buffer at 16°C overnight. The cloning procedure 
completed using restriction endonuclease digestion, 
sequencing (Macrogen Company, South Korea) and 
PCR of the insert using universal T7-promoter and T7-
terminator primers (TAG Copenhage A/S Symbion, 
Denmark). 
 
Expression of recombinant protein in E. coli BL21 strain  
In the expression stage, pET21b/cagA fragment was 
transformed into the E. coli BL21 strain as an expres-
sion host. For protein expression, IPTG (Isopropyl β-
D-1-thiogalactopyranoside) was used as an inducing 
material in different concentrations (0.2, 0.5 and 1 
mM), and then, to get the best time and temperature for 
induction of cells, different temperatures (4, 16, 18, 28 
and 37C) and for incubation, various times (4, 8, 16 
and 24 hr) were used. Next, collected cells were soni-
cated 3-4 times with one min interval between cycles. 
Cells were pelleted by use of centrifugation at 14,000x 
g for 15 min at 4C. The recombinant protein (CagA) 
was entered to the inclusion bodies (Insolubility phase) 
and for dissolving inclusion bodies and denaturation of 
protein expression in cells (Protein was in the pellet), 
6M guanidine HCl was used.  
 
SDS-PAGE  
SDS-PAGE technique was used with a concentra-
tion of 12% polyacrylamide gel at voltage of 120 V in 
the presence of the marker to verify the recombinant 
protein expression. Then, for staining of protein bands, 
Coomassie Brilliant Blue R250 was applied. Then, 
band size was judged in comparison to protein marker 
(Thermo scientific, US) 15.   
 
Purification of recombinant protein from E. coli lysate 
Because His-tag was inserted in vector and based on 
designed primers, nickel affinity chromatography resin 
(Ni-NTA chromatography) from QIAGEN Company 
was used for protein purification according to the pre-
vious study 16. The purity of the recombinant protein 
was characterized by the use of SDS-PAGE and West-
ern blotting techniques. Lastly, for the removal of im-
idazole and other waste constituents, dialysis was per-
formed by PBS buffer (pH=7.5) at 4°C overnight. The 
purity of the recombinant protein was characterized by 
the use of SDS-PAGE and Western blotting techni-
ques. Bicinchoninic Acid Protein Assay Kit (Parstoos) 
was used for determination of protein concentration. 
 
Western blotting technique  
In performing Western blotting technique, the sepa-
rated protein by SDS-PAGE gel was transmitted to 
PVDF membrane (Amersham) and immunoblotting 
was completed using anti-poly histidine-peroxidase 
monoclonal antibody (Sigma-Aldrich). Regarding the 
standard direction (Manufacturer’s direction), protein 
bands were finally shown by Chemiluminescent West-
ern Blot Kit (Parstoos). The antibody dilution of 1/7000 
was applied in this method 17. 
 
Patients 
Serum was taken from 10 patients referred to the in-
ternal ward of Shahid Beheshti hospital, Kashan in 
2018. Also, upper gastrointestinal endoscopy, biopsy 
specimens from the gastric antrum for hematoxylin/ 
eosin staining, and rapid urease test and culture were 
used for inclusion of patients with active ulcer disease 
and gastric cancer 2,18.  
 
Immunogenicity analysis  
Western blotting was performed according to the 
standard protocol as previously described using CagA 
antibodies and normal human sera as a negative control 




The spatial structure of the cagA gene is shown in 
figure 1. After receiving cagA construction in PGH 
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vector, confirmed by enzyme digestion, two fragments 
841 bp (cagA) and 2907 bp (PGH) were detected on 
gel agarose. After sub-cloning into the expression vec-
tor pET21b, checked by PCR, enzyme digestion (using 
BamHI and SalI) and two distinct bands 841 bp (cagA) 
and 5442 bp (pET21b) were detected and sequencing 
method was used for definitive confirmation. After 
that, sub-cloned pET21b (+) fragment was cloned into 
the expression host (E. coli strain BL21). The optimal 
temperature, IPTG concentration and time were 37°C 
and 0.2 mM and overnight, respectively. Because pro-
tein was entered into the insolubility phase as men-
tioned in the methodology section, 6 M guanidine HCl 
was used for dissolving inclusion bodies and denatura-
tion of protein expression in cells. Then, SDS page and 
Western blotting was carried out for CagA protein 
(Figures 2 and 3).  
 
Purification of recombinant protein from E. coli lysate 
Because the His-tag was inserted in vector and 
based on designed primers, nickel affinity chromatog-
raphy resin (Ni-NTA chromatography) from QIAGEN 
Company was used for protein purification according 
to the previous study (Figure 3). The Western blotting 
technique confirmed the immunogenicity of the re-
combinant CagA protein to human antiserum.  
Discussion 
 
CagA has been introduced as an oncoprotein be-
cause it is accompanied with severe pathological re-
sults and most patients with gastric cancer are CagA 
positive; also, its effects on tumor suppressor pathways 
have been shown 19. For gene expression, Esmaeili et 
al 20 used pET28 a (+) vector which contains T7 pro-
moter and E. coli, BL21 (DE3) host to produce recom-
binant CagA to a considerable amount. In another 
study, Farjadi et al 21 used prokaryotic expression vec-
tor pET32a and E. coli BL21 (DE3) as expression host. 
Both studies performed ligation at 16°C overnight, and 
double cut technique was used to clone cagA gene and 
applied antibiotic in both studies was kanamycin and 
the protein purification was done by nickel affinity 
chromatography resin (Ni-NTA chromatography) (QI-
AGEN, USA). Although cloning and expression of 
CagA protein by Tummuru has also been done previ-
ously, but because of its large size (120 kDa), experi-
ments like two mentioned studies were performed in 
this research with the use of pET21b (+) vector and 
BL21 (DE3); the applied antibiotic in the present study 
was kanamycin and expression of CagA antigen, in 
line with Han et al’s 10 study, led to the formation of 
inclusion body which is probably due to differences in 
the type of expression vector and designing. In previ-
ous studies, optimization has not been used but in the 
current study optimization and codon usage for the 
desired fragment was applied and consistent codons 
with expression host E. coli BL21 (DE3) was replaced 
instead of codons of its fragment. Existence in three 
reading frames, using IPTG as the inducer, also suita-
bility for expression of recombinant proteins due to 
protease deficiency in BL21 (DE3) are indicated as 
Figure 1. The three dimensional spatial structure of cagA protein 
using I-TASSER and Discovery Studio Software. 
Figure 2. Initial confirmation of CagA protein using SDS-PAGE. Left 
to right, Lanes 3 and 4 (Supernatant): Lane 3: BL21 non-induced, 
Lane 4: CagA protein. M: Protein Marker. Lanes 5 and 7 (Precipi-
tate): Lane 5: Non-induced BL21, Lane 7: Protein CagA. 
Figure 3. Left picture: SDS PAGE for purified recombinant protein. 
Lane 1: Protein marker and Lane 2 shows the protein 38 kDa (CagA). 
Right picture: Image related to Western blotting technique for con-
firmation of CagA expression.  Lane 2:  It corresponds to protein 38 
kDa (CagA), and Lane M: Protein marker. 
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benefits of all pET vectors and pET 21b has been 
shown as a commercially optimized vector 22. Ad-
vantages of expression of proteins in E. coli include 
easy and quick function besides low costs 23. CagA is 
one of the ideal antigens which can be applied for im-
provement of H. pylori vaccines. In our study, a CagA 
expression system of pET21b-cagA BL21 was success-




In conclusion, only 5′-end of recombinant protein 
CagA with high immunogenicity effects was success-
fully constructed, cloned and expressed.  Also, CagA 
recombinant protein showed good immunogenicity 
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